Core Viewpoint - The company has been recognized as a quality management benchmark in Guangxi for its "Practice of Granule Quality Control Team Building Experience," highlighting its commitment to quality management and operational excellence [1][6]. Group 1: Recognition and Achievements - The company successfully entered the 2025 Guangxi Industrial Enterprise Quality Management Benchmark list, receiving formal recognition and a plaque from the Guangxi Industrial and Information Technology Department [1]. - This recognition follows the team's previous achievement of the "National Worker Pioneer" title in 2023, showcasing the effectiveness of its quality management practices [7]. Group 2: Quality Management Practices - The granule production team operates under a "Precision, Standardization, and Refinement" GMP management system, aiming for zero defects through strict adherence to quality standards [6]. - The team has achieved a 100% training qualification rate for all employees, enhancing their technical skills and quality awareness [6]. - The team maintains quality standards that exceed national regulations, with moisture content controlled below 2% compared to the national standard of ≤8% [7]. Group 3: Future Plans and Goals - The company plans to leverage this recognition to further promote the granule production team's practices across all departments, aiming for higher standards in quality control and innovation [7]. - The company is committed to contributing to the high-quality development of Guangxi's industry by enhancing product and service quality [7].

Core Viewpoint - Shenwei Pharmaceutical (02877) reported a significant decline in revenue for the nine months ending September 30, 2025, with a total revenue of RMB 2.415 billion, representing a year-on-year decrease of 16.3% [1] Revenue Breakdown - The revenue from injection products decreased by 23.6% to RMB 786 million [1] - The revenue from soft capsule products decreased by 13.7% to RMB 337 million [1] - The revenue from granule products decreased by 14.5% to RMB 391 million [1] - The revenue from traditional Chinese medicine formula granules decreased by 11.8% to RMB 726 million [1] - The revenue from other dosage forms decreased by 6.1% to RMB 175 million [1]

Core Viewpoint - The company reported a significant decline in revenue for the nine months ending September 30, 2025, with a total revenue of RMB 2.415 billion, representing a 16.3% decrease compared to the same period in 2024 [1] Revenue Breakdown - Revenue from injection products decreased by 23.6% to RMB 786 million [1] - Revenue from soft capsule products decreased by 13.7% to RMB 337 million [1] - Revenue from granule products decreased by 14.5% to RMB 391 million [1] - Revenue from traditional Chinese medicine formula granules decreased by 11.8% to RMB 726 million [1] - Revenue from other dosage forms decreased by 6.1% to RMB 175 million [1] Product Contribution to Total Revenue - Injection products accounted for approximately 32.5% of total revenue [1] - Soft capsule products accounted for approximately 14.0% of total revenue [1] - Granule products accounted for approximately 16.2% of total revenue [1] - Traditional Chinese medicine formula granules accounted for approximately 30.1% of total revenue [1]